title: Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?
abstract: Inhibitor development in haemophilia patients is challenging especially when undergoing surgical procedures. The development of an inhibitor precludes using factor VIII (FVIII) therapy thereby requiring a bypassing agent (BPA) for surgical bleeding prophylaxis if the FVIII inhibitor titre >5 BU. Concomitant use of anti-inhibitor coagulant complex (AICC) and tranexamic acid has been reported in the literature as a beneficial treatment for this population. Anti-inhibitor coagulant complex is known to cause an increase in thrombin generation and tranexamic acid inhibits fibrinolysis. Hence, the combined used of AICC and tranexamic acid has been limited due to safety concerns over possibilities of increased risk of thrombotic events and disseminated intravascular coagulation. However, the rationale for concomitant therapy is to obtain a potential synergistic effect and to increase clot stability. We conducted a literature review of past studies and individual case reports of concomitant use of AICC and tranexamic acid, which was extensively used during dental procedures. Evidence also exists for concomitant use of the combined therapy in orthopaedic procedures, control of gastrointestinal bleeding, epistaxis and cerebral haemorrhages. Some patients who received the combined therapy had failed monotherapy with a single BPA prior to combined therapy. There were no reports of thrombotic complications related to the concomitant therapy and haemostasis was achieved in all cases. Anti-inhibitor coagulant complex and tranexamic acid therapy was found to be safe, well-tolerated and effective therapy in haemophilia patients with inhibitors. Additional randomized controlled studies should be performed to confirm these findings.
authors.affiliation: Rush University, Chicago, IL, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Valentino
authors.affiliation: Research Institute of Internal Medicine, Institute of Clinical Medicine, Oslo, Norway.|Department of Hematology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
authors.forename: P A
authors.initials: PA
authors.lastname: Holme
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D014148:Tranexamic Acid / Q000627:therapeutic use*
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D014148:Tranexamic Acid
keywords: anti-inhibitor coagulant complex; antifibrinolytic; bypassing therapy; haemophilia; inhibitors; tranexamic acid